Presented at STARS 2026. This project presents a comparative disproportionality analysis of adverse events associated with Inclisiran and Bempedoic Acid (BA) using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) from 2022–2024. Reporting Odds Ratios (RORs) were calculated to identify safety signal patterns for each drug. Inclisiran demonstrated stronger reporting signals for metabolic abnormalities—including increased triglycerides, elevated hepatic enzymes, increased LDL‑C, increased blood glucose, and death—while BA showed higher reporting of musculoskeletal and gastrointestinal symptoms such as myalgia, nausea, and arthralgia. These findings provide real‑world pharmacovigilance insights to support clinical decision‑making for non‑statin lipid‑lowering therapies. The project includes a poster summarizing background, methods, results, and implications for public health and clinical practice.
Use this login method if you
don't
have an
@illinois.edu
email address.
(Oops, I do have one)
IDEALS migrated to a new platform on June 23, 2022. If you created
your account prior to this date, you will have to reset your password
using the forgot-password link below.
